356results about How to "Promote oral absorption" patented technology

There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula:

wherein R^1a is a hydrocarbon group which may be substituted or a hydrogen atom,

• • ring A^a is a 6-membered aromatic ring which may be further substituted,
  • ring B^a is a homocyclic or heterocyclic ring which may be further substituted,
  • W^a is an oxygen atom or a sulfur atom,
  • X^a1 and X^a2, which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or X^a1 and X^a2 together may form an oxygen atom, a sulfur atom or NR^3a (wherein R^3a is a hydrocarbon group which may be substituted or a hydrogen atom), and
  • Y^a is C_1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

Novel compounds represented by the following formula (I) that act as a ligand to sigma receptor/binding cite and a medicament comprising the same as an active ingredient:

wherein X represents an alkyl group, an aryl group, a heterocyclic group or the like; Q represents a group represented by —CH₂—, —CO—, —O—, —CH(OR₇)— or the like wherein R₇ represents a hydrogen atom, an alkyl group or the like; n represents an integer of from 0 to 5; R₁ and R₂ each represent a hydrogen atom, an alkyl group or the like; B represents either of the following groups:

wherein R₃, R₄, R₅, and R₆ each represent a hydrogen atom, a halogen atom, an alkoxyl group or the like; m represents 1 or 2; and the ring of:

represents an aromatic heterocyclic ring.

The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na⁺/H⁺ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.

The present invention provides a particulate composition wherein an oil component containing reduced coenzyme Q₁₀ is polydispersed forming a domain in a matrix containing a water-soluble excipient, which simultaneously shows high oxidative stability and high oral absorbability, a production method thereof, and a stabilizing method thereof. It also provides a food, food with nutrient function claims, food for specified health uses, dietary supplement, nutritional product, animal drug, drink, feed, pet food, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like, which contain the composition.

The invention discloses a cyclohexane amine compound and application of the cyclohexane amine compound as anti-schizophrenia medicine. The cyclohexane amine compound has high affinity to a dopamine D3 receptor and a 5-HT1A, and representative compounds have a high selectivity of D3/D2 receptors. According to in vivo tests, the representative compounds such as I-1 compound can remarkably improve relative symptoms of apomorphine model mice and MK-801 model mice. The cyclohexane amine compound has the advantages of being good in anti-schizophrenia effect, low in acute toxicity and good in safety, and having development value of serving as novel high-efficiency and low-toxicity medicine for anti-neurological disorder diseases. The cyclohexane amine compound is a compound with a structural general formula (I) or stereomer, free alkali, aquo-complex or salt.

A self-emulsifying product of coix seed oil in the orally taken forms, such as softgel, liquid capsule, solid capsule, particle, etc, is proportionally prepared from coix seed, emulsifier, disperser, emulsifying aid, and solid adsorbent. It can be emulsified by itself in gastrointestinal tract for higher biologic utilization rate and higher curative effect. Its preparing process is also disclosed.

The invention belongs to the technical field of chemical synthetic medicines and particularly relates to water soluble salts of an organic acid of 5-(2-fluorophenyl)-N-methyl-1-(3-pyridyl sulfonyl)-1H-pyrrole-3-methylamine and an injection thereof for treating gastric acid related diseases and a preparation method thereof. The invention discloses the salts of the organic acid of 5-(2-fluorophenyl)-N-methyl-1-(3-pyridyl sulfonyl)-1H-pyrrole-3-methylamine shown as the following general formula in the specification, wherein n is 1 or 1/2 and HA is an organic acid. According to the salts of the organic acid, which are disclosed by the invention, the solubility of the salts in water or an artificial gastric and intestinal juice is far greater than TAK438, and the solubility of pyroglutamate and lactate in water is greater than 1g/mL.

A self-emulsified ganoderma spore oil in the form of soft capsule, liquid soft capsule, capsule, particle, etc is prepared from ganoderma spore oil, carrier, emulsifier, emulsifying assistant and/or adsorbent. Its preparing process is also disclosed.

Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric traction, serotonin, post-menopause, alcohol, monosodium glutamate, mastocytosis, atopic dermatitis, food-allergy or food intolerance, and mast cell activation syndrome, or against individual symptoms of SVFS, superficial vasodilation, feeling of warmth, itching (pruritus) and hives, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, or chalconoid compounds, with appropriate substitutions of their hydroxyl groups to render them water soluble or in combination with a pshospholipid or cyclodextrin to render them to have higher oral absorption, administered alone or together with an anti-superficial vasodilation dose of one or more of, olive kernel oil, a serotonin inhibitor, a prostaglandin inhibitor, willow bark extract. A composition for treating cardiovascular disease with niacin, but without eliciting the SVFS effects of niacin, has also been invented.

The present invention discloses a method for treating or preventing a bone disorder in a mammal in need thereof comprising orally administering to said mammal a pharmaceutically effective amount of a pharmaceutical composition of at least one bisphosphonate, or a pharmaceutically acceptable salt or esters thereof, and at least one aminoalky methacrylate copolymer, according to a dosing schedule having a dosing interval selected from once-weekly dosing, twice-monthly dosing, once-monthly, once-quarterly and once-annually dosing. The present invention further discloses a method for treating or preventing a bone disorder in a mammal in need thereof comprising continuously orally administering a unit dosage per-day to said mammal in a short time for a long time therapy.

The present invention relates to the compound represented by formula (I):

(wherein, all the symbols has the same meanings as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof.

Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.

The invention relates to the field of pharmaceutical preparations, in particular to a hydroxy safflor yellow A soft capsule preparation with high bioavailability, the invention is characterized in that the invention consists of hydroxy safflor yellow A, oily matrix and surfactant, and the invention also discloses the preparation method.

2-Amino-6-arylthiopurine phosphonate shows no toxicity (inhibition of bone marrow cell growth, mutagenicity, etc.) but a high antiviral activity, has an oral absorbability and a high safety and can be produced in a short process. Thus, use of this compound makes it possible to provide an excellent antiviral agent which can be efficiently produced.

The invention relates to preparation and application of oral insulin nanoparticles. The oral insulin nanoparticles mainly comprises a carrier of N-amino acid chitosan and medicinal insulin, are used for treating diabetes and have a better effect of reducing blood sugar.

The invention provides a controlled release dosing medicine core composition and an osmotic pump preparation comprising the medicine core composition. The medicine core composition comprises, by weight, 100 parts of an amphiphilic polymer carrier Soluplus, 5-200 parts of medicines, 0-50 parts of a surface active agent, 0-200 parts of a framework material having the controlled release effect, 100-200 parts of an osmotic pressure accelerant having the controlled release effect and 0-20 parts of other auxiliary materials acceptable in pharmacy; the low-solubility medicines are medicines with the in-water solubility smaller than or equal to 1 mg/mL and comprise indissolvable or insoluble medicines with the solubility smaller than or equal to 0.1 mg/mL in water and medicines with the solubility larger than 0.1 mg/mL and very slightly soluble medicines smaller than or equal to 1 mg/mL; the surface active agent is an anion surface active agent; and the other auxiliary materials acceptable in pharmacy comprises one or more kinds of a bonding agent, a coloring agent and a lubricating agent.

Provided is a pharmaceutical composition having improved oral absorption of a bisphosphonate drug, comprising at least one active substance selected from bisphosphonate drugs having non-permeability to a lipid biomembrane due to ionization and high water-solubility in vivo and having bioavailability of less than 10%, and at least one selected from biocompatible water-soluble chitosan, as essential ingredients.

The invention provides a use of low-molecular weight oligomannuronate in preparation of a drug or a health care product for preventing or treating Parkinson's disease. According to the invention, marine acidic polysaccharose as a raw material is prepared into a water-soluble low-molecular weight mannuronic acid compound. An experiment proves that the low-molecular weight mannuronic acid can be used for preventing and treating or improving Parkinson's disease, has obvious pharmacological effects and no toxic or side effects on nerve cells and can be taken for a long time. The low-molecular weight mannuronic acid is a marine natural product, has the advantages of rich resources, easy industrialization, high safety, unique structure and good oral absorption, and has a wide market application prospect in prevention and treatment of Parkinson's disease.

A berberine danshinolate used to prepare the medicines for treating chronic hepatism, diabetes, and its complications is prepared from berbeine and danshinolic acid or its derivative, which includes danshinolic acid A or B or their derivatives and metallic salts, the metallic salts of the derivatives of danshinolic acid A or B, and the red sage root's extract containing danshinolic acid A or B.